Three experts discuss HIV management with PrEP therapies, highlighting the major obstacles that can impact these patients and what can be done to improve their quality of life.
EP. 1: Common Barriers to PrEP Therapy
Carl Schmid, an HIV/PrEP advocate, provides an overview of PrEP therapy; Frank J. Palella Jr, MD, a clinician focused on HIV and infectious disease, delves into the diagnostic process.
EP. 2: Improving Access and Adherence to PrEP
Dr Palella Jr highlights how clinicians support patient access to PrEP and what his experiences have shown him about patient adherence with the available oral therapies.
EP. 3: The Value of PrEP as HIV Prevention
Lynne H. Milgram, MD, MBA, CPE, iterates the importance of PrEP as an HIV prevention tactic and how walk away and fill rates are evaluated.
EP. 4: How to Select the Right Type of PrEP for Patients
An expert authority explains the treatment selection process for a patient, as well as the different ways to administer PrEP.
EP. 5: A New Approval in the PrEP Therapeutic Landscape
Frank J. Palella, Jr discusses cabotegravir, a recently approved injectable PrEP medication, that was test in the HTPN 083 and -084 trials.
EP. 6: Understanding the Benefits of Multiple Options for PrEP Therapy
A clinician, advocate, and payer provide their expert knowledge on the multiple modalities of PrEP therapy and how some can be more beneficial than others.
EP. 7: Identifying the Right Patient for Injectable PrEP
Dr Lynne H. Milgram starts the conversation on choosing the right candidate for long-acting injectable PrEP, as well as how findings show it is cost effective.
EP. 8: Knowing the Ins and Outs of Injectable PrEP
Frank J. Palella Jr, MD, and Carl Schmid continue the discussion of patient selection for long-acting injectable PrEP and its cost effectiveness in comparison with other PrEP modalities.
EP. 9: Utilizing Data for Policies and Cost-Effectiveness of PrEP Agents
Dr Milgram focuses on the cost-effectiveness of cabotegravir as a long-acting injectable PrEP therapy and how providers and payers use data and real-world evidence to create PrEP policies.
EP. 10: Receiving Grade A Recommendations for Injectable PrEP and New Agents
Lynne H. Milgram, MD, MBA, CPE, speaks about the USPSTF Grade A recommendation for injectable cabotegravir and how it could affect emerging agents in the future.
EP. 11: The Social Determinants Affecting PrEP Use and Access
Carl Schmid and Dr Milgram discusses the disparities in education and access to PrEP in the patient populations that need these medications the most.
EP. 12: Enhancing Patient Education on PrEP Therapies
Drs Palella Jr and Milgram explains the disconnect between PrEP and patient education and comments on how to fix it.
EP. 13: Future Opportunities to Improve PrEP Access and Management
Carl Schmid and Lynne H. Milgram, MD, MBA, CPE, conclude with sharing ideas that can provide more substantial access to PrEP and battle unmet needs in PrEP management.
2 Clarke Drive Cranbury, NJ 08512